Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 7/20 | 0.52 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613137 | 1.00 | MEN1 (0.54) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL7610032 | 0.82 | BACE1 (0.71) | BACE1SLC6A11BCHE | |
| SCHEMBL7610027 | 0.82 | BACE1 (0.71) | BACE1SLC6A11BCHE | |
| SCHEMBL6891428 | 0.81 | BACE1 (0.57) | BACE1SLC6A11BCHE | |
| SCHEMBL7607054 | 0.81 | BACE1 (0.58) | BACE1SLC6A11BCHE | |
| SCHEMBL7611860 | 0.81 | BACE1 (0.57) | BACE1SLC6A11BCHE | |
| SCHEMBL7607057 | 0.81 | BACE1 (0.58) | BACE1SLC6A11BCHE | |
| SCHEMBL7611853 | 0.81 | BACE1 (0.57) | BACE1SLC6A11BCHE | |
| SCHEMBL6895248 | 0.80 | BACE1 (0.56) | BACE1SLC6A11BCHE | |
| SCHEMBL7607369 | 0.80 | BACE1 (0.56) | BACE1SLC6A11BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | MEN1 1558/4885KMT2A 1570/4885HPGD 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.